Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 5/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5246731 | 0.83 | ALDH1A1 (0.50) | CA1CA2CA9CRBNCA12 | |
| SCHEMBL3067241 | 0.80 | CA1 (0.70) | CA1CA2CA9CRBNCA12 | |
| SCHEMBL3065675 | 0.78 | EDNRB (0.43) | CA1CA2CA9CRBNCA12 | |
| SCHEMBL24762150 | 0.77 | S100A9 (0.51) | CA1CA2CA9CRBNCA12 | |
| SCHEMBL24761991 | 0.77 | WDR5 (0.51) | WDR5CA1CA2CA9CRBN | |
| SCHEMBL29764473 | 0.77 | WDR5 (0.51) | WDR5CA1CA2CA9CRBN | |
| SCHEMBL24762145 | 0.75 | CA1 (0.44) | CA1CA2CA9CRBNCA12 | |
| SCHEMBL24762564 | 0.75 | KDM4E (0.53) | CA1CA2CA9CRBNCA12 | |
| SCHEMBL24762053 | 0.74 | CRBN (0.68) | CA1CA2CA9CRBNCA12 | |
| SCHEMBL3051463 | 0.74 | CA12 (0.52) | CA1CA2CA9CRBNCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| EP-1433479-B1 | APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA | EISAI R&D MAN CO LTD (JP) | 2007-12-05 | — | — | EP | disclosed |
| US-7015241-B2 | Appetite-stimulating agents and remedies for anorexia | EISAI CO., LTD. (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-20040242628-A1 | Appetite-stimulating agents and remedies for anorexia | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20040235866-A1 | Lymphocytic activation inhibitor and remedial agent for autoimmune disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1433479-A1 | APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA | Eisai Co., Ltd (JP) | 2004-06-30 | — | — | EP | disclosed |
| EP-1430894-A1 | LYMPHOCYTIC ACTIVATION INHIBITOR AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE | Eisai Co. Ltd (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-0673937-B1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | EISAI CO LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | WDR5 2801/4885CA1 867/4885CA2 821/4885 |
| US-20040235866-A1 | Lymphocytic activation inhibitor and remedial agent for autoimmune disease | NFATC1, CHUK, CD4 | WDR5 2203/4885CA1 44/4885CA2 49/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | WDR5 2801/4885CA1 867/4885CA2 821/4885 |
| US-20040242628-A1 | Appetite-stimulating agents and remedies for anorexia | GHSR, CCKAR, SUCNR1 | WDR5 2664/4885CA1 219/4885CA2 208/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | WDR5 3223/4885CA1 827/4885CA2 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.